EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
Returns on capital
EyePoint Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-75.8%
avg -170.5%
ROIC
-74.5%
avg -51.9%
ROA
-63.7%
avg -49.3%
Analysis
ROA is currently the strongest return metric at -63.7% versus its period average of -49.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jay S. Duker | President, Chief Executive Officer & Director | USD 1.35M | 67 | 0 | <0.01% |
George O. Elston | Executive Vice President & Chief Financial Officer | USD 904.8K | 61 | — | — |
Ramiro Ribeiro | Chief Medical Officer | USD 888.56K | 43 | 0 | <0.01% |
David Scott Jones | Senior Vice President | USD 672.08K | 58 | 0 | <0.01% |
Tarek S. Hassan | Senior VP & Chief Strategic Science Officer | — | — | — | — |
Michael Campbell | Chief Commercial Officer | — | — | — | — |
Michael J. Maciocio | Chief Manufacturing Officer | — | — | — | — |
Ron I. Honig | Chief Legal Officer & Company Secretary | — | — | — | — |
Isabelle Lefebvre | Chief Regulatory Officer | — | — | — | — |
Jennifer Leonard | Chief People Officer & Senior Vice President of IT | — | — | — | — |
Marcia Sellos-Moura | Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$71,981.80
Sells
10
$2.01M
Net Transaction Value
−$1.94M
Net selling
Most Active
Ribeiro Ramiro
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 18, 26Aug 18, 2026 | Zaderej Karen L. Direct | Buy | $52.3K$52,258.00 |
| Jun 30, 26Jun 30, 2026 | Ribeiro Ramiro Direct | Sell | $36.6K$36,555.00 |
| Jun 30, 26Jun 30, 2026 | Ribeiro Ramiro Direct | Sell | $36.6K$36,611.93 |
| Apr 17, 26Apr 17, 2026 | Ribeiro Ramiro Direct | Sell | $36.6K$36,555.00 |
| Mar 16, 26Mar 16, 2026 | Duker Jay S. Indirect | Buy | $19.7K$19,723.80 |
| Mar 4, 26Mar 4, 2026 | Ribeiro Ramiro Direct | Sell | $43.6K$43,571.69 |
| Feb 17, 26Feb 17, 2026 | Ribeiro Ramiro Direct | Sell | $36.6K$36,555.00 |
| Jan 5, 26Jan 5, 2026 | Ribeiro Ramiro Direct | Sell | $727.3K$727,319.46 |
| Dec 4, 25Dec 4, 2025 | Cormorant Asset Management, LP Indirect | Sell | $942.2K$942,240.00 |
| Dec 4, 25Dec 4, 2025 | Lurker Nancy Direct | Sell | $140.5K$140,477.43 |
1–10 of 12
Summary
Insiders reported 2 buys worth $71,981.80 and 10 sells worth $2.01M over the last 12 months. That adds up to net selling of $1.94M. Ribeiro Ramiro was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -8.8% | +81.7% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.8% over three years. Forward estimates point to Revenue at +81.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does EyePoint Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EYPT's management, answered from reported figures.
Who manages EYPT?
EyePoint Pharmaceuticals, Inc. (EYPT) lists 11 active executives. The top listed executive is Tarek S. Hassan, Senior VP & Chief Strategic Science Officer.
Are EYPT insiders buying or selling?
Recent insider activity shows net buying of $41.41M.
Continue the stock analysis
Jump to another research area for this company.